CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,182,371 | -12.8% | 92,143 | +7.9% | 0.19% | -11.2% |
| Q2 2023 | $4,796,321 | +37.1% | 85,435 | +10.4% | 0.22% | +21.5% |
| Q1 2023 | $3,499,536 | +47.1% | 77,372 | +32.2% | 0.18% | +6.0% |
| Q4 2022 | $2,378,716 | -27.1% | 58,517 | +17.3% | 0.17% | -36.5% |
| Q3 2022 | $3,261,000 | +71.5% | 49,897 | +59.5% | 0.26% | +73.0% |
| Q2 2022 | $1,901,000 | +25.2% | 31,279 | +29.3% | 0.15% | +102.7% |
| Q1 2022 | $1,518,000 | -0.7% | 24,189 | +20.0% | 0.08% | +2.7% |
| Q4 2021 | $1,528,000 | +247.3% | 20,162 | +413.3% | 0.07% | +87.2% |
| Q3 2021 | $440,000 | -35.3% | 3,928 | -6.5% | 0.04% | -33.9% |
| Q2 2021 | $680,000 | -6.5% | 4,202 | -29.6% | 0.06% | -14.5% |
| Q1 2021 | $727,000 | -53.2% | 5,968 | -41.2% | 0.07% | -57.4% |
| Q4 2020 | $1,553,000 | +95.8% | 10,143 | +6.9% | 0.16% | +67.0% |
| Q3 2020 | $793,000 | – | 9,485 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |